ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.0
  1. ホーム
  2. /反応

Azetidine → 1-(azetidin-1-yl)-2-(3-fluoro-4-((((1R,2R)-2-(1-(5-(methoxymethyl) pyrimidin-2-yl)piperidin-4-yl)cyclopropyl)methoxy)methyl)phenyl)ethanone

HRID 1468877
ノート
印刷プレビュー

反応式

HRID 1468877 の反応式
[F:1][C:2]1[CH:3]=[C:4]([CH2:29][C:30](O)=[O:31])[CH:5]=[CH:6][C:7]=1[CH2:8][O:9][CH2:10][C@@H:11]1[CH2:13][C@@H:12]1[CH:14]1[CH2:19][CH2:18][N:17]([C:20]2[N:25]=[CH:24][C:23]([CH2:26][O:27][CH3:28])=[CH:22][N:21]=2)[CH2:16][CH2:15]1.O.O[N:35]1[C:39]2C=CC=[CH:43][C:38]=2N=N1.Cl.C(/N=N/CCCN(C)C)C.N1CCC1>C(Cl)Cl>[N:35]1([C:30](=[O:31])[CH2:29][C:4]2[CH:5]=[CH:6][C:7]([CH2:8][O:9][CH2:10][C@@H:11]3[CH2:13][C@@H:12]3[CH:14]3[CH2:15][CH2:16][N:17]([C:20]4[N:21]=[CH:22][C:23]([CH2:26][O:27][CH3:28])=[CH:24][N:25]=4)[CH2:18][CH2:19]3)=[C:2]([F:1])[CH:3]=2)[CH2:43][CH2:38][CH2:39]1
参加物実験手順後処理出典と根拠反応ノート

参加物

6

反応物 4

HCID 10422AzetidineHCID 27960291-Hydroxybenzotriazole hydrateHCID 867178062-(3-fluoro-4-((((1R,2R)-2-(1-(5-(methoxymethyl)pyrimidin-2-yl)piperidin-4-yl)cyclopropyl)methoxy)methyl)phenyl)acetic acidHCID 178465607HCID 178465607、化合物

生成物 1

HCID 711366761-(azetidin-1-yl)-2-(3-fluoro-4-((((1R,2R)-2-(1-(5-(methoxymethyl) pyrimidin-2-yl)piperidin-4-yl)cyclopropyl)methoxy)methyl)phenyl)ethanone
収率 76.3%

試薬・触媒・溶媒 1

HCID 6344Dichloromethane溶媒

実験手順

2-(3-Fluoro-4-((((1R,2R)-2-(1-(5-(methoxymethyl)pyrimidin-2-yl)piperidin-4-yl)cyclopropyl)methoxy)methyl)phenyl)acetic acid (Step D product, 70 mg, 0.158 mmol), 1-HYDROXYBENZOTRIAZOLE HYDRATE (36.3 mg, 0.237 mmol) and (E)-3-(ETHYLDIAZENYL)-N,N-DIMETHYLPROPAN-1-AMINE HYDROCHLORIDE (42.5 mg, 0.237 mmol) were dissolved in CH2Cl2 (3 ml). The mixture was stirred at RT for 10 min., to which was added AZETIDINE (0.016 ml, 0.237 mmol). The reaction mixture was stirred at RT overnight. TLC and LC-MS showed the SM was completely consumed. The mixture was diluted with DCM, washed with water, dried over MgSO4, and evaporated to dryness. The crude product was purified by prep TLC (pure EtOAc) to afford 58.2 mg (76%) of the title compound. 1H NMR (500 MHz, CDCl3) δ 8.30 (S, 2H), 7.38 (m, 1H), 7.05 (m, 2H), 4.70 (m, 2H), 4.60-4.50 (m, 2H), 4.25 (s, 2H), 4.10˜4.00 (m, 4H), 3.70 (m, 1H), 3.40 (m, 3H), 3.32 (s, 3H), 2.83 (m, 2H), 2.25 (m, 2H), 2.05 (m, 2H), 1.82 (m, 1H), 1.40-1.20 (m, 3H), 1.05 (m, 1H), 0.70 (m, 2H), 0.40 (m, 1H). LC/MS (m/z): 483 (M+H)+, GPR119 Human EC50: 5.16 nM.

後処理

  1. stirringThe reaction mixture was stirred at RT overnight
  2. customwas completely consumed
  3. additionThe mixture was diluted with DCM
  4. washwashed with water
  5. dry with materialdried over MgSO4
  6. customevaporated to dryness
  7. customThe crude product was purified by prep TLC (pure EtOAc)

出典と根拠

ORDレコード
ord-8ff19329d1954ee7840bdd25b7d8f2ef
出典データセット
uspto-grants-2015_04
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US09006228B2

反応ノート

読み込み中…

このページの内容参加物実験手順後処理出典と根拠反応ノート